hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06268431, orgStudyIdInfo id: 43084, briefTitle: Oxytocin Rest to Reduce Cesarean Delivery, acronym: ORCA, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-15, primaryCompletionDateStruct date: 2026-02-15, completionDateStruct date: 2026-03-15, studyFirstPostDateStruct date: 2024-02-20, lastUpdatePostDateStruct date: 2024-02-20, sponsorCollaboratorsModule leadSponsor name: Christiana Care Health Services, class: OTHER, descriptionModule briefSummary: Prolonged labor is usually managed with continuous oxytocin infusion. "Oxytocin rest" has been proposed as a strategy to resolve protracted labor in patients who have received continuous oxytocin without progress. This strategy involves discontinuing oxytocin then restarting infusion after a period of time, under the theory that washout of the oxytocin receptor will strengthen uterine contractions to improve labor progress. "Oxytocin rest" is performed on labor and delivery units across the United States. Yet, there is no randomized or prospective data to support the practice.The purpose of this study is to assess whether oxytocin rest of 60 minutes in patients with prolonged labor reduces risk for cesarean delivery., conditionsModule conditions: Prolonged Labor, conditions: Failed Induction, conditions: Labor Dystocia, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 350, type: ESTIMATED, armsInterventionsModule interventions name: Oxytocin rest, outcomesModule primaryOutcomes measure: Cesarean rate, secondaryOutcomes measure: Time to delivery (hours), secondaryOutcomes measure: Time to vaginal delivery (hours), secondaryOutcomes measure: Time to active labor (hours), secondaryOutcomes measure: Duration of active labor (hours), secondaryOutcomes measure: Composite maternal adverse outcome, secondaryOutcomes measure: Composite neonatal adverse outcome, secondaryOutcomes measure: Labor Agentry Scale score, secondaryOutcomes measure: Rate of intraamniotic infection (IAI), secondaryOutcomes measure: Rate of postpartum endometritis, secondaryOutcomes measure: Rate of postpartum hemorrhage, eligibilityModule sex: FEMALE, minimumAge: 18 Years, maximumAge: 55 Years, stdAges: ADULT, contactsLocationsModule locations facility: ChristianaCare Health System, status: RECRUITING, city: Newark, state: Delaware, zip: 19718, country: United States, contacts name: Teresa C Logue, role: CONTACT, phone: 302-733-6563, email: teresa.logue@christianacare.org, geoPoint lat: 39.68372, lon: -75.74966, documentSection largeDocumentModule largeDocs typeAbbrev: Prot_SAP, hasProtocol: True, hasSap: True, hasIcf: False, label: Study Protocol and Statistical Analysis Plan, date: 2024-01-21, uploadDate: 2024-02-11T17:37, filename: Prot_SAP_000.pdf, size: 239099, hasResults: False
protocolSection identificationModule nctId: NCT06268418, orgStudyIdInfo id: 2024PI020, briefTitle: Pre-therapeutic 68Ga-PSMA PET AI Based Dose Prediction for 177Lu-PSMA Targeted Radionuclide Therapy, acronym: PADL, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-31, primaryCompletionDateStruct date: 2024-06-30, completionDateStruct date: 2024-08-30, studyFirstPostDateStruct date: 2024-02-20, lastUpdatePostDateStruct date: 2024-02-21, sponsorCollaboratorsModule leadSponsor name: Central Hospital, Nancy, France, class: OTHER, descriptionModule briefSummary: Targeted Radionuclide Therapy (TRT) is a contemporary approach to radiation oncology, aiming to deliver the maximal destructive radiation dose via cancer-targeting radiopharmaceutical. Radioactive ligands for the prostate-specific membrane antigen (PSMA) have emerged for the treatment of metastatic castration-resistant prostate cancer (mCRPC).Normal organ and tumor dose can be assessed by a series of cross-sectional whole-body SPECT scans, however, these require a large amount imaging time and are often not feasible in routine clinical practice.An alternative is to generate a 3D time integrated activity (TIA) map per patient based on the PBPK and the pre-therapy imaging, conditionsModule conditions: Radionucleide Therapy, designModule studyType: OBSERVATIONAL, designInfo observationalModel: OTHER, timePerspective: RETROSPECTIVE, enrollmentInfo count: 46, type: ESTIMATED, armsInterventionsModule interventions name: Artificial intelligence, outcomesModule primaryOutcomes measure: Evaluate the prediction of the absorbed dose by Deep Learning approaches for RLT with 177Lu-PSMA, from pre-treatment 68Ga-PSMA.PET/CT images, secondaryOutcomes measure: Automatically contour the total tumor metabolic volume on 68Ga-PSMA pretreatment PET images using Deep Learning approaches, eligibilityModule sex: MALE, minimumAge: 18 Years, maximumAge: 99 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06268405, orgStudyIdInfo id: 22-5806, briefTitle: Positron Emission Mammography and Liquid Biopsy in Women With High-risk Breast Screenings, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-09-21, primaryCompletionDateStruct date: 2024-09-21, completionDateStruct date: 2024-09-21, studyFirstPostDateStruct date: 2024-02-20, lastUpdatePostDateStruct date: 2024-02-20, sponsorCollaboratorsModule leadSponsor name: University Health Network, Toronto, class: OTHER, descriptionModule briefSummary: The goal of this pilot research study is to compare two experimental tests, namely Liquid Biopsy and Positron Emission Mammography (PEM) in women at high risk of breast cancer. The plan for this study is to evaluate if findings from Liquid Biopsy can be matched to images obtained by PEM.Liquid Biopsy is a blood test that can detect early tumours in patients with malignancies, while PEM is an imaging tool equipped with a high-resolution camera that uses an injected positron emitting isotope to locate breast tumours. Participation in this study entails a blood draw for Liquid Biopsy test and a PEM imaging exam before undergoing a magnetic resonance imaging (MRI) - guided biopsy for a suspicious breast lesion.If correlations between paired samples are observed between imaging using PEM and the Liquid Biopsy data, further studies will be conducted to evaluate if these techniques can help refine screening investigations and ultimately reduce the unnecessary biopsies and anxiety in high-risk populations., conditionsModule conditions: Breast Cancer, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: SCREENING, maskingInfo masking: NONE, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: Liquid Biopsy, interventions name: Positron Emission Mammography (PEM), outcomesModule primaryOutcomes measure: Correlation of paired samples between Liquid Biopsy data and Positron Emission Mammography (PEM) images, eligibilityModule sex: FEMALE, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: University Health Network, status: RECRUITING, city: Toronto, state: Ontario, zip: M5G 2M9, country: Canada, contacts name: Samira Taeb, MSc, role: CONTACT, phone: 416-946-4501, phoneExt: 5853, email: samira.taeb2@uhn.ca, contacts name: Vivianne Freitas, role: CONTACT, phone: 416-946-2000, phoneExt: 5608, email: vivianne.freitas@uhn.ca, contacts name: Vivianne Freitas, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 43.70011, lon: -79.4163, hasResults: False
protocolSection identificationModule nctId: NCT06268392, orgStudyIdInfo id: CT-2023-11-20-001, briefTitle: A Comparative Study of AI Methods for Fetal Diagnostic Accuracy in Ultrasound, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-02-15, primaryCompletionDateStruct date: 2024-08-01, completionDateStruct date: 2024-08-01, studyFirstPostDateStruct date: 2024-02-20, lastUpdatePostDateStruct date: 2024-02-22, sponsorCollaboratorsModule leadSponsor name: Copenhagen Academy for Medical Education and Simulation, class: OTHER, collaborators name: Slagelse Hospital, collaborators name: Technical University of Denmark, collaborators name: Rigshospitalet, Denmark, descriptionModule briefSummary: This study serves as a supplemental investigation to the randomized controlled SCAN-AID study (NCT0632187). This study will evaluate and compare the fetal growth estimation outcomes of AI-supported groups, expert sonographers, and control groups using a secondary AI predictive model., conditionsModule conditions: Fetal Growth Retardation, conditions: Fetal Macrosomia, conditions: Fetal Growth, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: RETROSPECTIVE, enrollmentInfo count: 150, type: ESTIMATED, armsInterventionsModule, outcomesModule primaryOutcomes measure: Fetal weight, primaryOutcomes measure: Ultrasound fetal weight estimation, eligibilityModule sex: FEMALE, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06268379, orgStudyIdInfo id: #08-01-03-23, briefTitle: BMA and Dynamic Nomogram for Survival Prediction in Patients With CRC, statusModule overallStatus: COMPLETED, startDateStruct date: 2010-02-15, primaryCompletionDateStruct date: 2021-12-15, completionDateStruct date: 2021-12-15, studyFirstPostDateStruct date: 2024-02-20, lastUpdatePostDateStruct date: 2024-02-20, sponsorCollaboratorsModule leadSponsor name: Cabrini Health, class: OTHER, descriptionModule briefSummary: This project will examine the outstanding statistical techniques for predicting the survival of patients with colorectal cancer (CRC) (colorectal neoplasia database). The motivating clinical question that led to proposing this project is based on the general assumption that: "Right-sided colorectal cancer (CRC) has worse survival than left-sided CRC." The question is, which aspects of the patient's characteristics are responsible for this difference? This led us to BMA model selection and provide a clinician-friendly online nomogram., conditionsModule conditions: Colon Cancer, conditions: Model Disease, designModule studyType: OBSERVATIONAL, designInfo observationalModel: OTHER, timePerspective: PROSPECTIVE, enrollmentInfo count: 2475, type: ACTUAL, armsInterventionsModule interventions name: Surgery, outcomesModule primaryOutcomes measure: OS, primaryOutcomes measure: RFS, eligibilityModule sex: ALL, minimumAge: 22 Years, maximumAge: 101 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Cabrini Health, city: Melbourne, state: Victoria, zip: 3144, country: Australia, geoPoint lat: -37.814, lon: 144.96332, hasResults: False
protocolSection identificationModule nctId: NCT06268366, orgStudyIdInfo id: UEvansville, briefTitle: Effects of Exercise-Based Interventions on Symmio Self-Movement Screen, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-01, primaryCompletionDateStruct date: 2024-08-01, completionDateStruct date: 2025-03-01, studyFirstPostDateStruct date: 2024-02-20, lastUpdatePostDateStruct date: 2024-02-29, sponsorCollaboratorsModule leadSponsor name: University of Evansville, class: OTHER, descriptionModule briefSummary: Musculoskeletal screening for physical risk factors requires equipment and a trained healthcare or fitness professional to perform and interpret the scoring so that appropriate exercise interventions can be prescribed. However, barriers such as healthcare costs and accessibility, low perceived need to seek medical care, and previous unfavorable evaluation of seeking medical care are associated with healthcare avoidant behaviors. This research aims to explore the effectiveness of the Symmio Self-Screen application to generate specific exercise interventions to address an individual's associated physical risk factors. The ability of the Symmio application to prescribe a targeted exercise program which can reduce asymmetries, improve movement quality, and enhance overall function is unknown. Therefore, the purpose of this study is to determine the effectiveness of the Symmio application in designing individualized exercise interventions which target the unique movement limitations and asymmetries in adults., conditionsModule conditions: Movement Disorders, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, maskingDescription: The primary investigators and statisticians will be blinded to the group allocation, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 180, type: ESTIMATED, armsInterventionsModule interventions name: Exercise, outcomesModule primaryOutcomes measure: Symmio Self-Movement Screen, secondaryOutcomes measure: Global Rating of Change, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06268353, orgStudyIdInfo id: 109324-1, briefTitle: Is the Plasma Concentration of CAPGDF15 Increased in Pregnancy? A Pilot Study, acronym: CAP, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-15, primaryCompletionDateStruct date: 2026-03-15, completionDateStruct date: 2026-03-15, studyFirstPostDateStruct date: 2024-02-20, lastUpdatePostDateStruct date: 2024-02-26, sponsorCollaboratorsModule leadSponsor name: University of Copenhagen, class: OTHER, collaborators name: Stanford University, descriptionModule briefSummary: Background and Purpose During pregnancy, the hormone GDF15 rises between 100-200 times higher than before pregnancy. The significance of this dramatic increase is not clarified, but it has been shown that pregnant women with insufficient increase in GDF15 have a higher risk of spontaneous abortion. CAPGDF15 is a small peptide consisting of 12 amino acids recently found in plasma in both mice and humans, and this peptide is part of the prohormone from which GDF15 is synthesized. Therefore, the assumption is that CAPGDF15 is secreted simultaneously with GDF15. The significance of CAPGDF15 in the organism is completely unknown, except that injection into mice reduces food intake. Therefore, the investigators are interested in investigating whether there is a similar dramatic upregulation of CAPGDF15 as with GDF15 itself. The investigators will not set up a large-scale study without having some prior knowledge of whether this is indeed the case. Therefore, the investigators will conduct a pilot study on 3 pregnant women and 3 control women to examine whether there is any reason to proceed with an actual scientific experiment. Since the increase in GDF15 itself is very large at least100 fold, a pilot study involving only 3 pregnant women and 3 non-pregnant women will be sufficient to gain an impression of whether there is also a significant increase in CAPGDF15. The data will be used to assess whether an actual research project is worth establishing.Purpose:The purpose of conducting this pilot study is to investigate whether there is an upregulation of CAPGDF15 similar to that of the hormone GDF15 during pregnancy. By conducting a pilot study on 3 pregnant women and 3 control women, the investigators will see if this is actually the case before setting up an actual scientific experiment., conditionsModule conditions: Pregnancy Related, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SEQUENTIAL, interventionModelDescription: Non-pregnant controls and pregnant women, primaryPurpose: BASIC_SCIENCE, maskingInfo masking: NONE, enrollmentInfo count: 6, type: ESTIMATED, armsInterventionsModule interventions name: blood sampling, outcomesModule primaryOutcomes measure: CAPGDF15 levels in plasma, eligibilityModule sex: FEMALE, minimumAge: 18 Years, maximumAge: 40 Years, stdAges: ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06268327, orgStudyIdInfo id: Adjuvant treatment in BC, briefTitle: Adding Adjuvant Cisplatin and Gemicitabine Versus Capecitabine in Triple-negative Breast Cancer Patients in Non pCR After Neoadjuvant Standard Chemotherapy, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-30, primaryCompletionDateStruct date: 2025-10-30, completionDateStruct date: 2026-10-30, studyFirstPostDateStruct date: 2024-02-20, lastUpdatePostDateStruct date: 2024-02-20, sponsorCollaboratorsModule leadSponsor name: Assiut University, class: OTHER, descriptionModule briefSummary: In our study; investigator aim To show efficacy and toxicity of Adjuvant cisplatin and gemcitabine in triple-negative breast cancer patients with non pathologically complete response after neoadjuvant chemotherapy To compare outcome of adjuvant cisplatin and gemcitabine versus capecitabine, conditionsModule conditions: Breast Cancer, designModule studyType: INTERVENTIONAL, phases: PHASE2, phases: PHASE3, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: Cisplatin injection and gemcitabine, interventions name: Capecitabine tablets, outcomesModule primaryOutcomes measure: Adding adjuvant cisplatin and gemcitabine versus capecitabine in triple-negative Breast cancer patients with non pathologically complete response after neoadjuvant standard chemotherapy, secondaryOutcomes measure: Comparison of patients who receive cisplatin and gemcitabine versus capecitabine in Triple negative breast cancer, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06268314, orgStudyIdInfo id: hypoalbuminemia in pediatrics., briefTitle: Feeding Pattern and Hypoalbuminemia in Pediatrics With Chronic Kidney Disease., statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-01, primaryCompletionDateStruct date: 2026-03-01, completionDateStruct date: 2026-06-01, studyFirstPostDateStruct date: 2024-02-20, lastUpdatePostDateStruct date: 2024-03-05, sponsorCollaboratorsModule leadSponsor name: Assiut University, class: OTHER, descriptionModule briefSummary: To determine the impact of feeding pattern on the development of hypoalbuminemia and out come of pediatric patients with chronic kidney disease., conditionsModule conditions: Chronic Kidney Diseases, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 70, type: ESTIMATED, outcomesModule primaryOutcomes measure: Feeding Pattern and Hypoalbuminemia in Pediatrics With Chronic Kidney Disease., eligibilityModule sex: ALL, minimumAge: 2 Years, maximumAge: 16 Years, stdAges: CHILD, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06268288, orgStudyIdInfo id: 22-011492, briefTitle: Non-invasive Vagal Neurostimulation (nVNS) in Adolescents With Postural Orthostatic Tachycardia Syndrome (POTS), statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-02-12, primaryCompletionDateStruct date: 2024-07-22, completionDateStruct date: 2024-12-22, studyFirstPostDateStruct date: 2024-02-20, lastUpdatePostDateStruct date: 2024-02-20, sponsorCollaboratorsModule leadSponsor name: Mayo Clinic, class: OTHER, descriptionModule briefSummary: The purpose of this study is to determine if nVNS will decrease autonomic symptom intensity (COMPASS-31 and Child Functional Disability Inventory) in adolescent patients with postural orthostatic tachycardia syndrome (POTS) in comparison to standard recovery STEPS management., conditionsModule conditions: Postural Tachycardia Syndrome, conditions: Autonomic Dysfunction, conditions: Postural Orthostatic Tachycardia Syndrome, conditions: POTS - Postural Orthostatic Tachycardia Syndrome, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Half of the patient population will be randomized to standard management only. The other half of the population will be randomized to standard management plus use of the vagal nerve stimulator, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 40, type: ESTIMATED, armsInterventionsModule interventions name: GammaCore intervention, interventions name: STEPS management protocol, outcomesModule primaryOutcomes measure: The change in COMPASS-31 scores between individuals in both arms of the study, primaryOutcomes measure: The change in Child Functional Disability Inventory scores between individuals in both arms of the study, primaryOutcomes measure: The change in heart rate increase in head up tilt table tests in individuals in both arms of the study, secondaryOutcomes measure: Does nVNS influence headache frequency in adolescent patients with POTS, secondaryOutcomes measure: Does nVNS influence ability to increase exercise duration in adolescent patients with POTS, secondaryOutcomes measure: Does use of nVNS influence degree of depression in adolescent patients with POTS, eligibilityModule sex: ALL, minimumAge: 12 Years, maximumAge: 19 Years, stdAges: CHILD, stdAges: ADULT, contactsLocationsModule locations facility: Mayo Clinic in Rochester, city: Rochester, state: Minnesota, zip: 55905, country: United States, geoPoint lat: 44.02163, lon: -92.4699, hasResults: False
protocolSection identificationModule nctId: NCT06268275, orgStudyIdInfo id: HE651314, briefTitle: Comparison of Effects of Scalp Block and Intravenous Esmolol on Hemodynamic Response Following the Skull Pins Application for Elective Supratentorial Craniotomy, statusModule overallStatus: COMPLETED, startDateStruct date: 2022-09-19, primaryCompletionDateStruct date: 2024-02-01, completionDateStruct date: 2024-02-13, studyFirstPostDateStruct date: 2024-02-20, lastUpdatePostDateStruct date: 2024-02-20, sponsorCollaboratorsModule leadSponsor name: Khon Kaen University, class: OTHER, descriptionModule briefSummary: The goal of this clinical trial is to compare hemodynamic response (MAP, SBP, DBP and HR) between scalp block and intravenous esmolol while skull pins application in patients undergoing elective supratentorial craniotomy under general anesthesia., conditionsModule conditions: Hemodynamic Instability, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: RCT, primaryPurpose: PREVENTION, maskingInfo masking: TRIPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 90, type: ACTUAL, armsInterventionsModule interventions name: Scalp block, interventions name: Esmolol, outcomesModule primaryOutcomes measure: MAP, primaryOutcomes measure: SBP, primaryOutcomes measure: DBP, primaryOutcomes measure: HR, secondaryOutcomes measure: BIS, secondaryOutcomes measure: Cumulative postoperative opioids consumption, secondaryOutcomes measure: Postoperative adverse events, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Khon Kaen University, city: Khon Kaen, state: Naimuang, Muang, zip: 40002, country: Thailand, geoPoint lat: 16.44671, lon: 102.833, hasResults: False